Bibliographic Details
| Title: |
Discontinuing pimavanserin carries risk in treating dementia‐related psychosis. |
| Source: |
Brown University Psychopharmacology Update. Nov2021, Vol. 32 Issue 11, p1-5. 5p. |
| Subject Terms: |
*DRUG therapy for psychoses, *NASOPHARYNX diseases, *ALZHEIMER'S disease, *SEROTONIN antagonists, *URINARY tract infections, *TREATMENT effectiveness, *DISEASE relapse, *PARKINSON'S disease, *HEADACHE, *TERMINATION of treatment, *DISEASE complications, *OLD age |
| Abstract: |
A Phase 3 trial that was stopped early for efficacy found that continuation of pimavanserin beyond a 12‐week open‐label treatment period in patients with dementia‐related psychosis reduced the risk of relapse compared with patients in whom the drug was discontinued. The risk of treatment discontinuation for any reason was lower in patients receiving extended treatment compared with those who were switched to placebo, the researchers reported. Study results were published July 22, 2021, in the New England Journal of Medicine. [ABSTRACT FROM AUTHOR] |
|
Copyright of Brown University Psychopharmacology Update is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
